You are here

Validation of Cross-Species Biomarkers of DNA Damage

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44ES028163-01A1
Agency Tracking Number: R44ES028163
Amount: $172,660.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIEHS
Solicitation Number: PA16-302
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-01-15
Award End Date (Contract End Date): 2018-07-14
Small Business Information
Rochester, NY 14623-2860
United States
DUNS: 085992055
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (585) 442-0930
Business Contact
Phone: (585) 489-0256
Research Institution

Project Summary
This project will validate two high throughput human blood based DNA damage assays and develop them
into commercial kitsThe assays monitor types of damage associated with important human diseasesWhereas the PIG A assay reports on gene mutationthe micronucleated reticulocyteMN RETassay is
responsive to chromosomal breaks and or lossesThe biomarkers are applicable to both humans and
laboratory animals and will fulfill two important needsextension of findings in laboratory animal models to
direct studies in humansand performance of well controlled mechanistic laboratory studies to understand
observations first made in humansThe assays utilize immunomagnetic separation prior to flow cytometry to
dramatically enrich the relevant cell populations and thereby enhance assay precision and sensitivityBy
providing simple to use kits with thoroughly documented reproducibility and inter laboratory transferabilityand validating the biomarkers for specific usesresearchers will have available tools with unprecedented
efficiencies for comprehensively studying those factors that contribute to inter individual differences in
human DNA damageApplications include the study of drug treatmentshost and or life style factors that
contribute to inter individual differences in DNA damage and repairexaggerated sensitivities to antineoplastic therapiesand population based epidemiology studies of environmental exposuresincluding
occupational exposuresThe project benefits from a strong multidisciplinary team of internationally
recognized scientists with a proven track record of successfully converting research advances into reliable
commercial assay kits Project Narrative
This project will validate two high throughput human blood based DNA damage assays and develop them
into commercial kitsThe assays represent significant advances in the ability to directly monitor important
types of DNA damage in humansand their cross species nature is ideal for supporting mechanistic
laboratory studies when necessaryValidation work will include but is not limited to assessments of assay
reproducibility within and among laboratoriesvalidation of target cellsand identification of physiological
and lifestyle factors that affect assay resultsThe proposed work also includes the evaluation of several
important use cases for these kitsfor example studying DNA damage resulting from chemotherapiesand
also systemic inflammation

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government